Technical analysis of RenovoRx, Inc. (RNXT): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc.
Price Performance
| 1 month | +32.48% |
| 3 months | +68.48% |
| Year-to-date | +84.50% |
| 1 year | +27.05% |
| 3 years | +4.03% |
| 5 years | -79.58% |
52-Week Range
| 52-week High | $2.59 |
| 52-week Low | $0.70 |
| Avg Volume (90d) | 583K |
Technical Indicators
| SMA 50 | $1.31 |
| SMA 200 | $1.03 |
| Beta | 1.22 |
| 30-day Volatility (annualised) | 133.6% |
| Price vs SMA 50 | +18.7% |
| Price vs SMA 200 | +51.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $1.11 | |
| 2025-11 | $0.92 | -17.4% |
| 2025-12 | $0.84 | -8.4% |
| 2026-01 | $1.04 | +23.8% |
| 2026-02 | $0.88 | -15.1% |
| 2026-03 | $1.01 | +14.4% |
| 2026-04 | $0.85 | -15.8% |
| 2026-05 | $0.91 | +7.0% |
| 2026-06 | $0.98 | +7.8% |
| 2026-07 | $0.96 | -2.2% |
| 2026-08 | $1.93 | +101.4% |
| 2026-09 | $1.55 | -19.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $1.55 |
| Market Cap | $70M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 8.16 |
| EV / EBITDA | -8.01 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 5.74 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -8.04 |